Form 4: KEQU CFO Sells 2,000 Shares Under 10b5-1 Plan

Kewaunee Scientific Corp's Chief Financial Officer, Donald T. Gardner III, sold 2,000 shares of common stock for a weighted average price of $37.57 per share.

Summary

• Donald T. Gardner III, Chief Financial Officer and Director of Kewaunee Scientific Corp (KEQU), reported a sale of company common stock.
• The transaction involved the disposition of 2,000 shares of common stock.
• The shares were sold on January 6, 2026, at a weighted average price of $37.57 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan.
• Following this transaction, Mr. Gardner beneficially owns 9,564 shares of Kewaunee Scientific Corp common stock.
• The shares were sold in multiple transactions at prices ranging from $37.50 to $38.00.

Sentiment

Score: 5

Explanation: A neutral score is assigned because while it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal often associated with insider selling. It's a routine transaction for many executives managing their personal portfolios.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-arranged transaction rather than an immediate reaction to new, undisclosed information.

Negatives

• An insider sale, particularly by a Chief Financial Officer, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price, despite the transaction being under a 10b5-1 plan.

Future Outlook

NA

Management Comments

• The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This is an insider transaction and does not directly relate to broader industry trends or competitors, though general market sentiment towards insider selling can be influenced by industry-specific factors.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, though the 10b5-1 plan mitigates this. The reduction in direct insider ownership is minor relative to total shares outstanding.
• Employees, Customers, Suppliers, Creditors: Unlikely to have a direct impact from this specific insider transaction.

Next Steps

• NA

Key Dates

Recommendation

The sale by the CFO, while a reduction in insider ownership, was executed under a pre-arranged 10b5-1 plan, which suggests a planned portfolio management activity rather than a reaction to new negative company-specific news. Without additional context on company performance or strategic direction, this single transaction does not warrant a change from a 'hold' position. Investors should monitor future filings and company performance for more substantive indicators.

Keywords

Kewaunee Scientific Corp, KEQU, Insider Sale, Form 4, Donald T. Gardner III, CFO, Stock Transaction, 10b5-1 Plan